[Prevalence and associated factors of macrosomia in Peru, 2013]

Antonio José Ledo Alves da Cunha1, Manuel Sobrino Toro2, César Gutiérrez3

  • 1Faculdade de Medicina, Federal University of Rio de Janeiro. Rio de Janeiro, Brasil.

Insights

Macrosomia, a birth weight over 4000g, affects 5.3% of infants in Peru. Key associated factors include male sex, higher birth order, maternal obesity, and maternal height, with implications for delivery methods.

Area of Science:

  • Obstetrics and Gynecology
  • Public Health
  • Pediatrics

Background:

  • Macrosomia, defined as excessive birth weight, poses risks during childbirth and postpartum.
  • Understanding the prevalence and associated factors of macrosomia is crucial for maternal and child health strategies in Peru.

Purpose of the Study:

  • To determine the prevalence of macrosomia in Peru.
  • To identify sociodemographic and maternal factors associated with macrosomia.
  • To describe peri- and postpartum complications in macrosomic infants.

Main Methods:

  • Analysis of birth weight data from 6121 children under 5 years old from the 2013 Demographic and Family Health Survey (ENDES).
  • Logistic regression was employed to identify independent associations between sociodemographic factors and macrosomia.
  • Macrosomia was defined as a birth weight exceeding 4000g.

Main Results:

  • The prevalence of macrosomia in Peru was found to be 5.3%.
  • Independent risk factors for macrosomia included male infant sex, higher birth order, maternal obesity, and increased maternal height.
  • Macrosomic infants were significantly more likely to be delivered via Cesarean section (43.9%) compared to non-macrosomic infants (26.9%).

Conclusions:

  • Peru exhibits a relatively low prevalence of macrosomia compared to other low-to-middle income countries.
  • While most identified risk factors are unmodifiable, maternal obesity presents a target for intervention.
  • Preventing maternal obesity in women of childbearing age may reduce rates of macrosomia and Cesarean deliveries in Peru.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
2.1K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
316
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
324
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250
Bulimia Nervosa01:30

Bulimia Nervosa

Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
874